Latest News

PharmaTech Outlook Selects GenPro to be Among 2017's Top 10 Solution Providers to Biopharma Discovery and Development Organizations


Back

STARTUP GENPRO AIMS TO USE EPIGENETIC ANALYSIS TECH FOR BIOMARKER DISCOVERY, TEST DEVELOPMENT

University of Delaware spin-out Genome Profiling (“GenPro”) has developed the first epigenetic biomarker (EpiMarker™) discovery platform to analyze genome-wide methylation profiles from which it characterizes definitive biomarkers for early disease diagnosis and other clinically valuable applications.

GenPro Co-Founder and CSO Adam Marsh described the technology during a presentation at the Cambridge Healthtech Institute's Clinical Genome Conference in San Francisco in June 2015 to be fully compatible with standard NGS workflows and to include a of proprietary pre-NGS gDNA preparation kit matched to powerful post-NGS data analytics algorithms to enable one NGS run to deliver data for both genomic variant call data analyses AND highly sensitive epigenetic profiling and novel bio-marker discovery.

Dr. Marsh conveyed that the most widely used method for whole genome methylation profiling, which uses bisulfite oxidation as the gDNA pre-NGS sample preparation protocol, has several drawbacks. For one, it requires a large amount of starting material to obtain desired downstream methylation measurement sensitivity because there is significant DNA loss at each step during the chemical oxidation reactions. And at the end, due to the bisulfite conversion of the unmethylated cytosines to uracil, and their corresponding readout as adenine, mapping of the reads to the reference sequence becomes all the more difficult.

GenPro's DNA prep kit involves the use of restriction enzymes that do not chemically alter the DNA. Small sample gDNA sample sizes can be used and then because no DNA is destroyed GenPro’s post-NGS methylation profiling analytics measure and quantify methylation at all relevant CpG locations thereby providing much higher resolution methylation profiles that feed GenPro’s epigenetic biomarker discovery analytics.

GenPro is conducting collaborations with major clinical research institutions to discovery novel EpiMarkes for triple negative breast cancer and for discerning patients with acute myeloid leukemia who will be responsive to Vidaza treatment from those that will not.

Jeb Connor, GenPro’s CEO and Co-founder conveyed, “GenPro mission is to leverage our capabilities through collaborative 'lab-bench-to-bedside' partnerships with bio-pharma companies, diagnostic companies, and clinical research institutions to discover, elucidate and commercialize novel EpiMarkers™ that deliver high clinical value across many chronic and life threatening diseases and create new business growth opportunities for our partners.”

Is your lab, clinic, or pharmaceutical company ready to identify robust prognostic and/or diagnostic biomarkers of potentially high clinical and commercial value? Please contact us to explore the potential to collaborate.

The full article is available for a fee at: "GenomeWeb: Startup GenPro Aims to Use Epigenetic Analysis Tech for Biomarker Discovery, Test Development"

GenPro invites potential collaborators to contact us and explore partnerships,

Is your lab, clinic, or pharmaceutical company ready to identify robust prognostic and/or diagnostic biomarkers of potentially high clinical and commercial value? Please contact us to explore the potential to collaborate.

Contact us via Email: info@genprollc.com or fill out the contact form here and we will get back to you soon.